Pancreatic Cancer

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

By

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

BRCA Status Could Inform Pancreatic Cancer Management

BRCA Status Could Inform Pancreatic Cancer Management

By

The development of BRCA-targeted therapies might offer the best opportunities to bring pancreatic cancer into the precision-oncology era.

Hepatitis B Infection May Increase the Risk for Pancreatic Cancer

Hepatitis B Infection May Increase the Risk for Pancreatic Cancer

Investigators assessed the association of hepatitis B infection and pancreatic cancer, along with predictors of pancreatic cancer and mortality.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

By

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Pancreatic Cancer and New-Onset Diabetes

Pancreatic Cancer and New-Onset Diabetes

By

New-onset adult diabetes mellitus appears to be both a risk factor for and a sequelae of pancreatic cancer.

Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

By

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

By

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

Identifying Potential Targets for Companion Diagnostic Tests Using Poly-Ligand Profiling

Identifying Potential Targets for Companion Diagnostic Tests Using Poly-Ligand Profiling

By

Researchers identified potential targets for a companion diagnostic tests using poly-ligand profiling (PLP) to determine which patients with locally advanced or metastatic pancreatic cancer may benefit from gemcitabine plus evofosfamide.

Longer Overall Survival with FOLFIRINOX Versus Gemcitabine/nab-Paclitaxel in Pancreatic Cancer

Longer Overall Survival with FOLFIRINOX Versus Gemcitabine/nab-Paclitaxel in Pancreatic Cancer

By

Prior to this study, there were no conclusive data directly comparing these regimens.

Eosinophil-to-Lymphocyte Ratio Associated with Shorter Survival in Pancreatic Cancer

Eosinophil-to-Lymphocyte Ratio Associated with Shorter Survival in Pancreatic Cancer

By

Are systemic inflammatory biomarkers in the blood potential prognostic markers of overall survival in pancreatic cancer?

Baseline Appetite Associated With Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma

Baseline Appetite Associated With Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma

By

A study reported post-hoc subgroup analyses of the international phase 3 NAPOLI-1 trial.

Better Quality of Life With Nab-Paclitaxel Added to Gemcitabine in Pancreatic Cancer

Better Quality of Life With Nab-Paclitaxel Added to Gemcitabine in Pancreatic Cancer

By

The combination of nab-paclitaxel plus gemcitabine improved quality of life scores and increased time to deterioration compared with gemcitabine monotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).

Six Genes Determined to Be 'Clearly Linked' to Pancreatic Cancer Risk

Six Genes Determined to Be 'Clearly Linked' to Pancreatic Cancer Risk

By

In addition to linking six distinct genes to the disease, researchers found that a prior family history of pancreatic cancer alone cannot predict the presence of cancer-associated germline mutations.

<i>ARID1A</i> Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

By

New findings bolster the case for the predictive utility of ARID1A mutations.

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

By

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Chemoradiotherapy Before Surgery May Improve Outcomes in Resectable Pancreatic Cancer

Chemoradiotherapy Before Surgery May Improve Outcomes in Resectable Pancreatic Cancer

By

Evidence suggests that neoadjuvant chemoradiotherapy may afford benefit, but this hypothesis requires further validation.

mFOLFIRINOX After Resection May Lead to Improved Outcomes in Pancreatic Carcinoma

mFOLFIRINOX After Resection May Lead to Improved Outcomes in Pancreatic Carcinoma

By

Previous studies demonstrated that FOLFIRINOX is more effective than gemcitabine as first-line treatment for patients with metastatic pancreatic cancer with good performance status.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

By

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

By

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Preoperative Chemotherapy May Improve Margin-negative Resection Rates, Survival Outcomes in Pancreatic Cancer

Preoperative Chemotherapy May Improve Margin-negative Resection Rates, Survival Outcomes in Pancreatic Cancer

By

Researchers enrolled 50 previously untreated patients with newly diagnosed and borderline resectable pancreatic cancer.

The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

By

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

Pancreatic Cancer and the Microbiome — In the Clinic

Pancreatic Cancer and the Microbiome — In the Clinic

By

In the future, targets of drug development may be within the microbiome.

HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

By

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

Neoadjuvant Chemotherapy May Confer Benefit in Pancreatic Adenocarcinoma

Neoadjuvant Chemotherapy May Confer Benefit in Pancreatic Adenocarcinoma

By

The addition of preoperative chemotherapy may eradicate micrometastatic disease and direct postoperative therapy in the case of resistance.

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

By

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

By

Phase 1 trials should be considered therapeutic options for some patients.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs